Lung Cell-State Profiles in Chronic Respiratory Disease: Mechanisms, Clinical Implications, and Emerging Therapies

Abstract

Chronic respiratory diseases (CRDs) such as chronic obstructive pulmonary disease (COPD), asthma, and idiopathic pulmonary fibrosis (IPF) represent a significant global health burden, characterized by progressive loss of lung function and heterogeneous pathological processes. Recent advances in single-cell transcriptomics have enabled detailed mapping of lung cell-state profiles, revealing dynamic changes in epithelial, endothelial, and immune cell populations in CRDs. This review synthesizes current evidence on lung cell-state alterations in chronic respiratory disease, elucidates their mechanistic contributions to disease pathogenesis, and discusses implications for diagnosis, risk stratification, and targeted therapy. Emphasis is placed on integrating cell-state data into clinical practice and exploring the potential of cell-state targeted interventions.

Introduction

Chronic respiratory diseases (CRDs) encompass a spectrum of disorders marked by persistent airway inflammation, tissue remodeling, and impaired gas exchange. With morbidity and mortality rates continuing to rise globally, there is increasing emphasis on understanding the cellular and molecular underpinnings of these conditions. The advent of high-resolution single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics has revolutionized our understanding of lung biology, enabling detailed analysis of distinct cell populations, their functional states, and intercellular interactions in health and disease. This review aims to provide clinicians and researchers with an updated synthesis of lung cell-state profiles in CRDs, highlighting both the foundational mechanisms and clinically actionable insights derived from recent studies.

Epidemiology / Disease Burden

CRDs are among the leading causes of morbidity and mortality worldwide. According to the World Health Organization, COPD alone affects over 300 million individuals globally and is projected to become the third leading cause of death by 2030. Asthma affects approximately 262 million people, while IPF and other interstitial lung diseases, though less common, carry high mortality rates. The socioeconomic impact is substantial, encompassing frequent hospitalizations, reduced productivity, and long-term disability. Notably, the prevalence and outcomes of CRDs are influenced by geographic, demographic, and environmental factors, necessitating context-specific approaches to management and research.

Pathophysiology

At the core of CRD pathogenesis are alterations in lung cell-state profiles distinct transcriptional and functional identities acquired by epithelial, mesenchymal, immune, and vascular cells in response to chronic injury and inflammation. In COPD, for example, basal and club cells undergo aberrant differentiation, while loss of alveolar type II cells impairs epithelial repair. In asthma, airway epithelial cells exhibit a pro-inflammatory, mucus-secreting phenotype, often accompanied by expansion of Th2 and ILC2 immune subsets. In IPF, reprogramming of alveolar epithelial cells and activation of fibrogenic myofibroblasts drive relentless extracellular matrix deposition. These cell-state transitions are orchestrated by epigenetic modifications, cytokine signaling, and cellular crosstalk, ultimately resulting in airway remodeling, fibrosis, and progressive loss of lung function.

Risk Factors

Multiple risk factors converge to promote maladaptive lung cell-state changes in CRDs. Tobacco smoke remains the most significant environmental risk factor for COPD, inducing oxidative stress, DNA damage, and persistent inflammation. Occupational exposures (e.g., silica, asbestos), air pollution, and respiratory infections contribute to both COPD and IPF. Genetic predisposition, exemplified by alpha-1 antitrypsin deficiency in COPD and mutations in surfactant protein genes in IPF, modulate susceptibility and disease severity. In asthma, atopy, family history, and early-life exposures to allergens and viral infections play central roles. Recent studies implicate aging and cellular senescence as universal drivers of aberrant cell states across CRDs.

Clinical Features

CRDs present with overlapping but distinct clinical features. COPD is characterized by chronic cough, sputum production, and exertional dyspnea, often with fixed airflow limitation. Asthma features episodic wheezing, variable airflow obstruction, and airway hyperresponsiveness. IPF and other interstitial lung diseases typically manifest with progressive dyspnea, dry cough, and inspiratory crackles. Importantly, the clinical phenotype may correlate with underlying cell-state profiles; for example, mucus hypersecretion in asthma and COPD is linked to goblet cell metaplasia, while fibrotic progression in IPF reflects persistent activation of profibrotic myofibroblasts and altered epithelial cell states.

Diagnosis

Accurate diagnosis relies on integrating clinical assessment with pulmonary function testing, imaging, and, increasingly, molecular profiling. Spirometry remains the cornerstone for differentiating obstructive (COPD, asthma) from restrictive (IPF) ventilatory defects. High-resolution computed tomography (HRCT) delineates emphysematous changes, airway wall thickening, and fibrotic patterns. Bronchoalveolar lavage and tissue biopsy provide cellular and molecular data, with emerging use of single-cell transcriptomics and proteomics to identify disease-specific cell-state signatures. Biomarkers such as periostin, YKL-40, and circulating extracellular vesicles are under investigation for non-invasive monitoring of cell-state changes and disease progression.

Treatment & Management

Management strategies are informed by disease phenotype, severity, and comorbidities. In COPD, bronchodilators, inhaled corticosteroids, and phosphodiesterase inhibitors target airway inflammation and bronchoconstriction, while smoking cessation remains paramount. Asthma therapy is guided by the stepwise use of inhaled corticosteroids, long-acting beta-agonists, and biologic agents (e.g., anti-IgE, anti-IL-5) for severe eosinophilic phenotypes. In IPF, antifibrotic drugs (pirfenidone, nintedanib) slow disease progression but do not reverse established fibrosis. Oxygen therapy, pulmonary rehabilitation, and lung transplantation are reserved for advanced disease. Personalized approaches incorporating cell-state profiling are under active exploration for tailoring therapy and predicting response.

Recent Advances / Emerging Therapies

Recent advances in single-cell and spatial omics have redefined our understanding of lung cell heterogeneity and dynamic cell-state transitions in CRDs. Studies have identified novel pathogenic cell states, such as transitional epithelial cells expressing markers of both alveolar and airway lineages, and profibrotic macrophage subtypes in IPF. Targeted therapies aimed at modulating specific cell-state transitions such as senolytics to eliminate senescent cells, and inhibitors of key signaling pathways (e.g., Notch, Wnt, TGF-β) are under preclinical and early clinical evaluation. Cell-based therapies, including mesenchymal stem cell infusions and epithelial progenitor cell transplantation, hold promise for regenerative intervention. Integration of cell-state data into clinical algorithms offers potential for earlier detection, risk stratification, and precision targeting of therapy.

Guideline Recommendations

Current clinical guidelines from international societies (GOLD, GINA, ATS/ERS) emphasize a multidimensional approach to CRD management, incorporating symptom assessment, lung function monitoring, and exacerbation prevention. While cell-state profiling is not yet standard in guidelines, there is growing recognition of its potential to inform endotyping, predict therapeutic response, and guide novel interventions. The incorporation of omics-derived biomarkers, especially in severe or treatment-refractory cases, is anticipated as technology becomes more accessible and evidence for clinical utility increases. Multidisciplinary collaboration and integration of molecular data into electronic health records are recommended to optimize patient outcomes.

Conclusion

The elucidation of lung cell-state profiles in chronic respiratory disease marks a paradigm shift in our understanding of disease mechanisms, heterogeneity, and therapeutic opportunities. By bridging basic science with clinical practice, cell-state mapping offers a foundation for precision medicine approaches that can improve diagnosis, risk assessment, and targeted treatment. Ongoing research and technological advances promise to further refine these insights, ultimately transforming the care of patients with chronic respiratory diseases.